Aripiprazole in autism spectrum disorders and fragile X syndrome.

Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics
Craig A EricksonChristopher J McDougle

Abstract

Autism spectrum disorders (ASDs) are childhood onset developmental disorders characterized by impairment of social skills and repetitive behavior, and also for classic autistic disorder, a significant impairment of communication. In addition to these core symptom domains, persons with ASDs frequently exhibit interfering behavioral symptoms, including irritability marked by aggression, self-injurious behavior, and severe tantrums. Aripiprazole is an atypical or newer generation antipsychotic with a unique mechanism of action impacting dopaminergic and serotonergic neurotransmission. The drug has been found efficacious for several indications, including most recently for use targeting irritability associated with autistic disorder in youth. Fragile X syndrome is the most common inherited cause of developmental disability and the most common known single gene cause of ASDs. As in idiopathic ASDs, irritable behavior is often exhibited by persons with fragile X syndrome. However, research to date in this disorder has not focused on this target symptom cluster. An initial pilot study has begun to assess the impact of aripiprazole on irritability in youth with fragile X syndrome.

References

Jan 16, 1998·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J Arnt, T Skarsfeldt
Jul 14, 2001·Journal of Autism and Developmental Disorders·D B BaileyG Mesibov
Dec 18, 2001·American Journal of Medical Genetics·C JohnstonA Reiss
Jun 14, 2002·European Journal of Pharmacology·Shaun JordanC Anthony Altar
Jun 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·Kevin D BurrisPerry B Molinoff
Aug 2, 2002·The New England Journal of Medicine·James T McCrackenUNKNOWN Research Units on Pediatric Psychopharmacology Autism Network
Dec 6, 2002·The New England Journal of Medicine·Louis Sandler
Mar 1, 2003·Psychopharmacology·Daniel E CaseyUNKNOWN Aripiprazole Study Group
Jun 5, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David A ShapiroRichard Mailman
Mar 3, 2004·Mental Retardation and Developmental Disabilities Research Reviews·Elizabeth Berry-Kravis, Kristina Potanos
Jan 15, 2005·Journal of Child and Adolescent Psychopharmacology·Kimberly A StiglerChristopher J McDougle
Sep 27, 2005·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·David HesslRandi J Hagerman
May 16, 2006·American Journal of Medical Genetics. Part a·Deborah D HattonPenny Mirrett
May 30, 2006·Biological Psychiatry·George M AndersonBenedetto Vitiello
Oct 31, 2006·Journal of Child and Adolescent Psychopharmacology·Maria R Valicenti-McDermott, Howard Demb
Dec 15, 2006·Brain : a Journal of Neurology·David HesslRandi J Hagerman
Oct 4, 2007·Pediatric Annals·Craig A EricksonChristopher J McDougle
Jun 24, 2008·American Journal of Medical Genetics. Part a·Donald B BaileyDavid B Holiday
Jan 2, 2009·Pediatrics·Randi J HagermanMichael Tranfaglia
Jun 13, 2009·Journal of Child and Adolescent Psychopharmacology·Kimberly A StiglerChristopher J McDougle
Jul 18, 2009·Journal of Autism and Developmental Disorders·Craig A EricksonChristopher J McDougle
Oct 3, 2009·Journal of the American Academy of Child and Adolescent Psychiatry·Ronald N MarcusMichael G Aman
Feb 15, 2011·Psychopharmacology·Craig A EricksonChristopher J McDougle

❮ Previous
Next ❯

Citations

Feb 15, 2011·Psychopharmacology·Craig A EricksonChristopher J McDougle
Apr 5, 2013·Psychopharmacology·Laura C Politte, Christopher J McDougle
Feb 10, 2016·Drugs·Matthew H DavenportCraig A Erickson
Sep 25, 2010·Trends in Molecular Medicine·Josien LevengaRob Willemsen
Mar 15, 2015·Behavioural Pharmacology·Małgorzata HołujAgnieszka Nikiforuk
Feb 8, 2011·Expert Opinion on Pharmacotherapy·Cristan Ann Farmer, Michael G Aman
Dec 24, 2013·Drug Discovery Today·Jill L Silverman, Jacqueline N Crawley
Nov 16, 2013·The International Journal of Neuropsychopharmacology·Jantine A C BroekSabine Bahn
Dec 23, 2014·Neurología : publicación oficial de la Sociedad Española de Neurología·A PuginM A Alliende
Jul 8, 2017·Expert Opinion on Investigational Drugs·Lynn McClellanCraig A Erickson
Dec 9, 2017·Nature Reviews. Drug Discovery·Elizabeth M Berry-KravisSébastien Jacquemont
Jun 28, 2016·The Cochrane Database of Systematic Reviews·Lauren E Hirsch, Tamara Pringsheim
Feb 28, 2019·Current Treatment Options in Neurology·Isha JalnapurkarJean A Frazier
Sep 30, 2017·Nature Reviews. Disease Primers·Randi J HagermanPaul J Hagerman
Jul 9, 2011·American Journal of Medical Genetics. Part a·Filomena PirozziGiovanni Neri
Nov 23, 2019·Journal of Autism and Developmental Disorders·Heather Fielding-GebhardtNancy C Brady
Jan 6, 2019·Brain Sciences·Katherine C OkoniewskiDonald B Bailey
Apr 27, 2012·Journal of Intellectual Disability Research : JIDR·S S HallA L Reiss
Apr 13, 2011·Journal of Neurodevelopmental Disorders·Elizabeth Berry-KravisCrystal Hervey
Mar 10, 2011·Current Opinion in Neurology

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asperger Syndrome

Asperger syndrome (AS), also known as Asperger's, is a developmental disorder characterized by significant difficulties in social interaction and nonverbal communication, along with restricted and repetitive patterns of behavior and interests. Discover the latest research on Asperger syndrome here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Autism

Autism spectrum disorder is associated with challenges with social skills, repetitive behaviors, and often accompanied by sensory sensitivities and medical issues. Here is the latest research on autism.